FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Eisai/Biogen Report Promising Alzheimers Data

Eisai and Biogen report new data from a lecanemab Alzheimers Phase 3 trial that suggest treated patients with early Alzheimers disease had reduced bra...

latest-news-card-1
Human Drugs

Ferrings Fecal Microbiota Product Approved for C.diff

FDA approves Ferring Pharmaceuticals Rebyota (fecal microbiota) for preventing recurrence of Clostridioides difficile infection in individuals 18 year...

latest-news-card-1
Medical Devices

Ex-BD Official Seeks DoJ Referral Against Company

A former Becton Dickinson safety official petitions FDA to refer the company to the U.S. Justice Department for allegedly violating the False Claims A...

latest-news-card-1
Human Drugs

Objectionable Conditions at Arbor Eyecare

FDA warns Arbor Centers for EyeCare about objectionable conditions in its conduct of two clinical investigations.

latest-news-card-1
Federal Register

Guide on Fecal Microbiota Enforcement Policy

Federal Register notice: FDA makes available a final guidance entitled Enforcement Policy Regarding Investigational New Drug Requirements for Use of F...

latest-news-card-1
Human Drugs

CDER Hearing Delay on NDA is Unfounded: Lexicon

Lexicon asks that its NDA for sotagliflozin be approved to treat Type 1 diabetes or that a hearing be held to resolve issues of fact about the NDA.

latest-news-card-1
Human Drugs

Suggestions to Improve OTC Drug Draft Reg

Five stakeholders recommend changes to an FDA proposed rule on nonprescription drug products with an additional condition for nonprescription use.

latest-news-card-1
Human Drugs

Roche Withdraws Tecentriq Bladder Cancer Indication

Roche withdraws a Tecentriq (atezolizumab) accelerated approval indication for treating certain adults with locally advanced or metastatic urothelial ...

latest-news-card-1
Federal Register

Mylan Requests Sulfamylon Withdrawal

Federal Register notice: FDA withdraws the approval of Mylans Sulfamylon (mafenide acetate, USP) powder for 5% topical solution after the company requ...

latest-news-card-1
Human Drugs

Skinny Labels Lead to Earlier Competition: Study

Researchers document the Medicare savings associated with skinny label biosimilars.